Compare · ACHV vs QUIT
ACHV vs QUIT
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Achieve Life Sciences Inc. (QUIT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and QUIT operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ACHV is the larger of the two at $697.7M, about 1.1x QUIT ($651.4M).
- ACHV has been more active in the news (5 items in the past 4 weeks vs 1 for QUIT).
- ACHV has more recent analyst coverage (11 ratings vs 0 for QUIT).
- Company
- Achieve Life Sciences Inc.
- Achieve Life Sciences Inc.
- Price
- -
- -
- Market cap
- $697.7M
- $651.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 5
- 1
- Recent ratings
- 11
- 0
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Achieve Life Sciences Inc.
AchieveRx, The Quit Company (Nasdaq: ACHV; QUIT effective November 10, 2026 ; formerly doing business as Achieve Life Sciences, Inc. ) is a late-stage pharmaceutical company with a singular focus on nicotine dependence. AchieveRx's mission is to develop medicine for people who want to quit smoking or vaping. That medicine is cytisinicline, an investigational compound. Three ideas guide the Company: simplicity, science, and second chances, for good.
Latest ACHV
- SEC Form 10-Q filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- SEC Form 4 filed by Achieve Life Sciences Inc.
- SEC Form 3 filed by Achieve Life Sciences Inc.